

**Institutional Review Board
Minutes
October 15, 1996**

Present: Ann Ekes, Ernie Graham, Paul Hansen, Keith Maxwell, Lisa Neal

The board met to discuss and act on protocol #9697-03. Discussion related to the potential risk to human subjects included concerns regarding the effects of chromium picolinate on insulin and the fact that most of the chromium picolinate supplements on the market also contain niacin.

The board voted 5-0 to approve the protocol provided that the following two conditions were met. 1) Subjects with a history of insulin-dependent diabetes mellitus should be excluded from participating in the study. 2) The primary investigator must determine whether the particular brand of supplement that will be used in the study contains niacin. If so, the known possible adverse reactions to niacin must be explicitly stated on the consent form.

Ekes will send a letter to the investigator and his faculty advisor informing them of the board's action.